Estimaciones de analistas de Wall Street para Kiniksa Pharmaceuticals International, plc (KNSA): precio objetivo de consenso, recomendaciones de compra/mantener/venta y previsiones de ingresos, BPA y EBITDA para los próximos ejercicios.
Consenso de analistas
| Compra fuerte | 0 |
| Compra | 11 |
| Mantener | 0 |
| Venta | 0 |
| Venta fuerte | 0 |
| Analistas totales | 11 |
| Calificación media (1-5) | 1.00 |
Sorpresas de Resultados Recientes
| Fecha | BPA Real | BPA Estimado | vs Est. |
|---|---|---|---|
| 2026-10-27 | $0.39 | ||
| 2026-07-28 | $0.30 | $0.30 | +0.2% |
| 2026-04-28 | $0.27 | $0.18 | +50.0% |
| 2026-02-24 | $0.17 | $0.29 | -41.4% |
| 2025-10-28 | $0.23 | $0.33 | -30.3% |
| 2025-07-29 | $0.23 | $0.18 | +27.8% |
| 2025-04-29 | $0.11 | $0.02 | +450.0% |
| 2025-02-25 | $-0.12 | $-0.06 | -100.0% |
Ratios de valoración
| Ratio P/E | 70.23 |
| Precio / Valor contable | 8.91 |
| EV / EBITDA | 49.60 |
| Rentabilidad por dividendo | 0.00% |
Cuenta de Resultados (10 años)
| Año | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Ingresos | 0 | 0 | 0 | 0 | 0 | $38.5M | $220.2M | $270.3M | $423.2M | $677.6M |
| Coste de Ventas | $22000 | $28000 | $286000 | $3.3M | $3.8M | $9.1M | $22.9M | $56.5M | $60.9M | $307.4M |
| Beneficio Bruto | -$22000 | -$28000 | -$286000 | -$3.3M | -$3.8M | $29.4M | $197.3M | $213.7M | $362.3M | $370.1M |
| I+D | $17.4M | $56.4M | $86.6M | $132.9M | $109.6M | $99.3M | $65.5M | $76.1M | $111.6M | $96.9M |
| Generales y Administrativos | $6.6M | $9.0M | $21.6M | $33.8M | $43.9M | $85.9M | $98.0M | $129.4M | $168.0M | $196.3M |
| Gastos Operativos | $24.0M | $65.4M | $108.2M | $166.7M | $153.6M | $186.1M | $187.5M | $238.9M | $407.9M | $292.9M |
| Beneficio Operativo | -$24.0M | -$65.4M | -$108.2M | -$170.0M | -$157.4M | -$156.6M | $9.8M | -$25.2M | -$45.6M | $77.2M |
| EBITDA | -$24.0M | -$65.4M | -$107.9M | -$160.6M | -$152.4M | -$154.2M | $13.4M | -$14.3M | -$34.5M | $90.4M |
| Gastos por Intereses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Beneficio Antes de Impuestos | -$23.9M | -$64.9M | -$103.4M | -$163.9M | -$156.2M | -$156.5M | $11.0M | -$16.7M | -$36.2M | $88.9M |
| Impuestos | $36000 | $2000 | -$214000 | -$2.0M | $5.2M | $1.4M | -$172.3M | -$30.7M | $7.0M | $29.9M |
| Beneficio Neto | -$24.0M | -$64.9M | -$103.2M | -$161.9M | -$161.4M | -$157.9M | $183.4M | $14.1M | -$43.2M | $59.0M |
| BPA | $-0.74 | $-2.00 | $-3.49 | $-2.99 | $-2.61 | $-2.30 | $2.64 | $0.20 | $-0.60 | $0.80 |
| BPA Diluido | $-0.74 | $-2.00 | $-3.49 | $-2.99 | $-2.61 | $-2.30 | $2.60 | $0.20 | $-0.60 | $0.75 |
| Acciones en Circulación (Diluidas) | $32.5M | $32.5M | $29.5M | $54.0M | $61.8M | $68.6M | $70.4M | $71.9M | $71.4M | $79.0M |
Precio
| Precio | $77.62 |
| Capitalización | $5.9B |
| Bolsa | NASDAQ |
| País | GB |
Empresas relacionadas: ADPT · APLS · CDTX · CPRX · FOLD · IDYA · MLYS
Explorar sector: Healthcare · Medical - Pharmaceuticals
Más secciones de KNSA: Resumen · Financieros · Valoración · Estadísticas · Técnico · Propiedad · Noticias · Eventos
Descubre más: Radar — señales de acciones infravaloradas · Academia de Inversión — aprende a analizar acciones